OcuTerra Therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
50 Milk St Fl 16, Boston, Massachusetts,...Phone Number
(617) 701-7382Website
www.ocuterratx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About OcuTerra Therapeutics
OcuTerra is focused on creating innovative solutions for the treatment of ophthalmic diseases, particularly diabetic retinopathy. Their lead product, OTT166, is a topical eye drop designed to provide earlier and non-invasive treatment options, potentially transforming the standard of care. The company aims to address significant unmet needs in the field of eye health. Their target clients include patients suffering from diabetic retinal disease and healthcare professionals involved in ophthalmic care.Explore more
OcuTerra Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OcuTerra Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
OcuTerra Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once OcuTerra Therapeutics has new funding data
Earning: See what the market has to say on OcuTerra Therapeutics recently announced quarterly report
Click to see if OcuTerra Therapeutics had a recent Job posting/layoffs
Check if OcuTerra Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at OcuTerra Therapeutics
Product Launch: Get notified when OcuTerra Therapeutics launches new products
Check out if OcuTerra Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined OcuTerra Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to OcuTerra Therapeutics
Compare insights from companies similar to OcuTerra Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OcuTerra Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OcuTerra Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OcuTerra Therapeutics.
OcuTerra Therapeutics financials insights
Gather financial insights about OcuTerra Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$35M
OcuTerra Therapeutics Tech Stack
A closer look at the technologies used by OcuTerra Therapeutics
Most Recent Scoops
Event
Events
New Hire
Executive Move
Event
Events
Event
Events
New Hire
Executive Move
OcuTerra Therapeutics News & Media
OcuTerra Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics announces President and CEO Kerrie Brady will present at the J.P. Morgan Healthcare Conference in San Francisco on January 11.OcuTerra Therapeutics Announces Last Patient Completes Final Visit in Nesvategrast (OTT166) Eye Drop Phase 2 DR:EAM Clinical Trial in Diabetic Retinopathy
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics announces the completion of the last patient’s final visit in the Phase 2 DR:EAM clinical trial of nesvategrast (OTT166).AAO 2023: OcuTerra's CEO shares update on diabetic retinopathy treatment study
Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.OcuTerra President and CEO Kerrie Brady Named to 2023 PharmaVoice 100 List of Most Inspiring Leaders
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics announces President and CEO Kerrie Brady has been named to this year's PharmaVoice 100 list.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding OcuTerra Therapeutics
Sign Up For FreeTo access detailed company insights
OcuTerra is focused on creating innovative solutions for the treatment of ophthalmic diseases, particularly diabetic retinopathy. Their lead product, OTT166, is a topical eye drop designed to provide earlier and non-invasive treatment options, potentially transforming the standard of care. The company aims to address significant unmet needs in the... Read More
